0000000000916380

AUTHOR

Wolfgang Saeger

showing 2 related works from this author

First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors

2021

AbstractAlthough non-functioning pituitary tumors are frequent, diagnostic and therapeutic concepts are not well standardized. We here present the first German multidisciplinary guideline on this topic. The single most important message is to manage the patients by a multidisciplinary team (consisting at least of an endocrinologist, a neurosurgeon, and a (neuro-) radiologist). The initial diagnostic work-up comprises a detailed characterization of both biochemical (focusing on hormonal excess or deficiency states) and morphological aspects (with magnetic resonance imaging of the sellar region). An ophthalmological examination is only needed in presence of symptoms or large tumors affecting …

medicine.medical_specialtyAdenomaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedizin030209 endocrinology & metabolism03 medical and health sciencesTherapeutic approach0302 clinical medicineEndocrinologyGermanyInternal MedicinemedicineHumansPituitary NeoplasmsNeuroradiologyPatient Care Teammedicine.diagnostic_testbusiness.industryPituitary tumorsMagnetic resonance imagingGeneral MedicineGuidelinemedicine.diseaseMagnetic Resonance ImagingRadiation therapyPractice Guidelines as TopicRadiologyNeurosurgerybusiness030217 neurology & neurosurgeryExperimental and Clinical Endocrinology & Diabetes
researchProduct

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germa…

2021

Abstract Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). Results Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had pre…

MaleOncologymedicine.medical_specialtyEndocrinology Diabetes and Metabolismchromogranin AMedizindiarrheacarcinoid syndromeOctreotideAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsPeptides CyclicArticleflushing03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeGermanyInternal medicineOutcome Assessment Health CareInternal MedicinemedicineClinical endpointHumansAgedMalignant Carcinoid Syndromebiologybusiness.industryChromogranin AGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumorsquality of lifeTolerabilityAustria030220 oncology & carcinogenesisbiology.proteinFemaleObservational studySomatostatinbusinessCarcinoid syndromemedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct